AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS

AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , YouTube and Threads .

CONTACT: Amgen, Thousand Oaks
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (investors)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-webcast-of-2025-second-quarter-financial-results-302518785.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
Group of male and female scientists working in laboratory.

Inside the ASX Biotech Boom: What’s Fuelling the Next Wave

Australia’s healthcare and biotechnology sector has matured into one of the most promising and strategically important segments of the ASX. Fortunes can shift on a single clinical trial result. A company with no revenue today could be a global contender tomorrow — if its science holds up. As... Keep Reading...
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks of 2025

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks.After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 4 Canadian Biotech Stocks of 2025

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here, the Investing News Network profiles the four best-performing Canadian biotech stocks... Keep Reading...
Scientist pouring blue liquid from a test tube into a flask in a lab.

Biotech Market Forecast: Top Trends for Biotech in 2026

The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is setting the stage for a continued recovery, driven in part by the integration of artificial intelligence (AI). Dr.... Keep Reading...
Hanlim & Korean Government Fund Pathway to Clinical Trial

Hanlim & Korean Government Fund Pathway to Clinical Trial

Invion Limited (IVX:AU) has announced Hanlim & Korean Government Fund Pathway to Clinical TrialDownload the PDF here. Keep Reading...
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...

Interactive Chart

Latest Press Releases

Related News